Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs
Summary
Its financings include crossover investments, the kind of deals that bring together financial backers for companies preparing to go public. Garabedian says the PXV fund’s roots were planted in the early discussions that brought Perceptive on board as a Xontogeny investor. Garabedian says the fund will invest primarily in startups focused on developing new drugs, though it could also put some of that money into new kinds of medical technologies and diagnostics tools. In a space that’s dominated by biologic drugs, the Landos compound is a small molecule that could potentially offer an equivalent benefit with fewer side effects. The rare disease drug developer is coming out of stealth Tuesday with a $17 million Series A investment led by PXV.
Funding
Review available funding amount, funding date, investors, and linked company information related to Perceptive Unveils New $210M Fund to Invest in Early-Stage Biotechs in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
